长期通气支持对肌萎缩侧索硬化患者及其家属生活质量的影响 (ALS-LTMV)
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is two to three years. The patient physical and psychological sufferings in ALS are immense, and apart from Riluzole, there is no effective treatment. Care of advanced ALS have an estimated cost of 4-8 million NOK per year. Perhaps the most challenging topic of ALS care is the decision to extend ventilation support into the stages of disease that require treatment both during day and night. In these cases, treatment is clearly life-sustaining and although quality of life may be maintained, the burden of caregiving imposed upon family or health care workers is huge, regardless of tracheostomy (TIV) or non-invasive (NIV) modality.
The present study is a longitudinal questionnaire study in Norway measuring overall quality of life, health-related quality of life, and disease-specific quality of life in ALS patients, partners and children before and after the introduction of life sustaining ventilation support. The investigators aim to increase the knowledge on how life-sustaining ventilation support with NIV or TIV affects the quality of life in ALS patients, life partners and children. The results from the study may provide crucial information for clinicians and patients on one of the most difficult ethical issues of ALS treatment. The investigators anticipate that this information will facilitate a shared decision making processes, weighing benefits and disadvantages in a wider perspective.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Ole-Bjørn Tysnes
- 电话号码:+ 47 55975063
- 邮箱:ole-bjorn.tysnes@helse-bergen.no
研究联系人备份
- 姓名:Tale Litlere Bjerknes
- 电话号码:+47 55975045
- 邮箱:tale.litlere.bjerknes@helse-bergen.no
学习地点
-
-
-
Bergen、挪威
- 招聘中
- Haukeland University Hospital
-
接触:
- Ole-Bjørn Tysnes
- 电话号码:+4755975063
- 邮箱:ole-bjorn.tysnes@helse-bergen.no
-
Lørenskog、挪威
- 招聘中
- Akershus University Hospital
-
首席研究员:
- Ola Nakken
-
接触:
- Ola Nakken
-
Oslo、挪威
- 招聘中
- Oslo University Hospital
-
首席研究员:
- Angelina Maniaol
-
接触:
- Angelina Maniaol
-
Sarpsborg、挪威、1714
- 尚未招聘
- Østfold Hospital Kalnes
-
接触:
- Sophie Cranner Seip, MD
- 电话号码:+47 69 86 00 00
- 邮箱:Sophie.Cranner.Seip@so-hf.no
-
Stavanger、挪威
- 招聘中
- Stavanger University Hospital
-
首席研究员:
- Katrin Ruth Schlüter
-
接触:
- Katrin Ruth Schlüter
-
Tromsø、挪威
- 招聘中
- Universitetssykehuset Nord-Norge
-
接触:
- Agnethe Eltoft, MD
- 电话号码:+4777627075
- 邮箱:agnethe.eltoft@unn.no
-
接触:
- Monica Vold, MD
- 邮箱:monica.linnea.vold@unn.no
-
首席研究员:
- Agnethe Eltoft, MD
-
首席研究员:
- Monica Vold, MD
-
Trondheim、挪威
- 招聘中
- St. Olavs Hospital
-
接触:
- Eivind Brønstad, MD PhD
-
首席研究员:
- Eivind Brønstad, MD PhD
-
-
Nordland
-
Bodø、Nordland、挪威、8005
- 招聘中
- Nordland Hospital Bodø
-
接触:
- Ane Sjulstad, MD
- 电话号码:+47 75571000
- 邮箱:Ane.Skaare.Sjulstad@nordlandssykehuset.no
-
-
Vest Agder
-
Kristiansand、Vest Agder、挪威
- 招聘中
- Sørlandet Hospital Trust
-
接触:
- Hildegunn Øverlie, MD
- 电话号码:+ 47 38073000
- 邮箱:hildegunn.overlie@sshf.no
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria for patients:
- A clinical diagnosis of probable ALS according to the revised El Escorial criteria
- Progression of the illness leading the consulting physician to offer treatment with LTMV
- Can communicate in Norwegian
Inclusion criteria for partners of ALS patients:
- Partner of a patient with ALS with progression of the illness leading the consulting physician to offer treatment with LTMV
- Can communicate in Norwegian
Inclusion criteria for children:
- Children from 8 years and older having a parent who suffers from ALS with progression of the illness leading the consulting physician to offer treatment with LTMV
- Can communicate in Norwegian
Exclusion criteria for patients, partners and children of ALS patients:
1. Potential participants with cognitive impairment or dementia.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:选择 LTMV 延长生命治疗的 ALS 患者及其家人
|
Patients that choose life prolonging treatment with long term mechanical ventilation support |
|
有源比较器:拒绝使用 LTMV 延长生命的 ALS 患者及其家人
|
Patients that decline life prolonging treatment with long term mechanical ventilation support |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall quality of life assessed by the "Quality of Life Scale"
大体时间:At inclusion
|
"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life. |
At inclusion
|
|
Overall quality of life assessed by the "Quality of Life Scale"
大体时间:3 months after inclusion
|
"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life. |
3 months after inclusion
|
|
Overall quality of life assessed by the "Quality of Life Scale"
大体时间:9 months after inclusion
|
"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life. |
9 months after inclusion
|
|
Overall quality of life assessed by the "Quality of Life Scale"
大体时间:15 months after inclusion
|
"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life. |
15 months after inclusion
|
|
Overall quality of life assessed by the "Quality of Life Scale"
大体时间:21 months after inclusion
|
"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life. |
21 months after inclusion
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Health-related quality of life assessed by the "EQ-5D-5L"
大体时间:At inclusion
|
"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life. |
At inclusion
|
|
Health-related quality of life assessed by the "EQ-5D-5L"
大体时间:3 months after inclusion
|
"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life. |
3 months after inclusion
|
|
Health-related quality of life assessed by the "EQ-5D-5L"
大体时间:9 months after inclusion
|
"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life. |
9 months after inclusion
|
|
Health-related quality of life assessed by the "EQ-5D-5L"
大体时间:15 months after inclusion
|
"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life. |
15 months after inclusion
|
|
Health-related quality of life assessed by the "EQ-5D-5L"
大体时间:21 months after inclusion
|
"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life. |
21 months after inclusion
|
|
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
大体时间:At inclusion
|
"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state |
At inclusion
|
|
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
大体时间:3 months after inclusion
|
"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state |
3 months after inclusion
|
|
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
大体时间:9 months after inclusion
|
"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state |
9 months after inclusion
|
|
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
大体时间:15 months after inclusion
|
"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state |
15 months after inclusion
|
|
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
大体时间:21 months after inclusion
|
"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state |
21 months after inclusion
|
|
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
大体时间:At inclusion
|
"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state. |
At inclusion
|
|
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
大体时间:3 months after inclusion
|
"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state. |
3 months after inclusion
|
|
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
大体时间:9 months after inclusion
|
"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state. |
9 months after inclusion
|
|
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
大体时间:15 months after inclusion
|
"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state. |
15 months after inclusion
|
|
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
大体时间:21 months after inclusion
|
"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state. |
21 months after inclusion
|
|
Health-related quality of life assessed by "Kidsscreen-27"
大体时间:At inclusion
|
"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life. |
At inclusion
|
|
Health-related quality of life assessed by "Kidsscreen-27"
大体时间:3 months after inclusion
|
"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life. |
3 months after inclusion
|
|
Health-related quality of life assessed by "Kidsscreen-27"
大体时间:9 months after inclusion
|
"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life. |
9 months after inclusion
|
|
Health-related quality of life assessed by "Kidsscreen-27"
大体时间:15 months after inclusion
|
"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life. |
15 months after inclusion
|
|
Health-related quality of life assessed by "Kidsscreen-27"
大体时间:21 months after inclusion
|
"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life. |
21 months after inclusion
|
|
Caregiver burden assessed by "Zarit Burden Interview"
大体时间:At inclusion
|
"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden). |
At inclusion
|
|
Caregiver burden assessed by "Zarit Burden Interview"
大体时间:3 months after inclusion
|
"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden). |
3 months after inclusion
|
|
Caregiver burden assessed by "Zarit Burden Interview"
大体时间:9 months after inclusion
|
"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden). |
9 months after inclusion
|
|
Caregiver burden assessed by "Zarit Burden Interview"
大体时间:15 months after inclusion
|
"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden). |
15 months after inclusion
|
|
Caregiver burden assessed by "Zarit Burden Interview"
大体时间:21 months after inclusion
|
"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden). |
21 months after inclusion
|
合作者和调查者
合作者
调查人员
- 首席研究员:Ole-Bjørn Tysnes、Haukeland University Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.